The Company has today received notification that Helium Special Situations Fund holds 8,275,000 ordinary shares in the Company representing 3.70% of the Company’s issued voting share capital.
For Further Information:
|
Dr Richard Goodfellow, Joint CEO
|
Scancell Holdings Plc |
+ 44 (0) 74 2323 0497 |
|
Professor Lindy Durrant, Joint CEO
|
Scancell Holdings Plc |
|
|
Camilla Hume/Stephen Keys
|
Cenkos Securities Plc |
+44 (0) 20 7397 8900
|
| Mo Noonan/Simon Conway |
FTI Consulting |
+ 44 (0) 20 7831 3113
|
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.